28.72EUR+2.43%Mkt Cap: 983.13M EURP/E: —Last update: 2026-05-14
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting in…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)112.52
PEG—
P/B-29.60
P/S30.31
EV/EBITDA-96.82
EV/Revenue28.56
EPS (TTM)-0.61
EPS (Forward)0.24
Cash Flow & Leverage
FCF Yield-1.46%
FCF Margin-44.22%
Operating CF19.46M EUR
CapEx (TTM)1.66M EUR
Net Debt/EBITDA-2.10
Net Debt20.09M EUR
Technical
SMA 5023.37 (+22.9%)
SMA 20024.83 (+15.7%)
Beta1.00
S&P 52W Chg24.23%
Avg Vol (30d)104.88K
Avg Vol (10d)119.14K
Technical Indicators
RSI (14)72.4
MACD1.2560
MACD Signal0.8880
MACD Hist.+0.3680
BB Upper28.58 EUR
BB Middle25.23 EUR
BB Lower21.89 EUR
BB Width26.51%
ATR (14)1.336 EUR
Vol Ratio (20d)0.78x
52W Range
15.0056% of range39.68
52W High39.68 EUR
52W Low15.00 EUR
Profitability
Gross Margin100.00%
EBITDA Margin-29.50%
Profit Margin-72.19%
Oper. Margin-46.74%
ROE112.65%
ROA-20.38%
Revenue Growth49.90%
Earnings Growth—
Balance Sheet
Debt/Equity-3.59
Current Ratio2.88
Quick Ratio2.83
Book Value/Sh-0.9250 EUR
Cash/Share1.616 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.35.91M
Float30.23M
Insiders35.05%
Institutions31.90%
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)34.44 EUR
Target Range29.20 EUR – 43.00 EUR
# Analysts11
Company
Market Cap983.13M EUR
Enterprise Value926.44M EUR
Revenue (TTM)32.44M EUR
Gross Profit25.54M EUR
Net Income (TTM)-18.44M EUR
Revenue/Share1.026 EUR
Fiscal Year EndMar 2025
MR QuarterSep 2025
Employees145
Last Price28.72 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0004065605